Skip to main content

Aurinia Pharmaceuticals (AUPH) was downgraded to a Hold Rating at RBC Capital

Tipranks - Tipranks - Wed Nov 5, 2025

In a report released today, Douglas Miehm from RBC Capital downgraded Aurinia Pharmaceuticals to a Hold, with a price target of $15.00. The company’s shares closed today at $14.27.

Meet Your ETF AI Analyst

According to TipRanks, Miehm is a 3-star analyst with an average return of 4.0% and a 48.62% success rate. Miehm covers the Healthcare sector, focusing on stocks such as MannKind, Bausch Health Companies, and WELL Health Technologies Corp.

Currently, the analyst consensus on Aurinia Pharmaceuticals is a Moderate Buy with an average price target of $13.25.

See today’s best-performing stocks on TipRanks >>

Based on Aurinia Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $70.01 million and a net profit of $21.51 million. In comparison, last year the company earned a revenue of $57.19 million and had a net profit of $722 thousand

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is neutral on the stock.

Read More on AUPH:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).